The Evolving Treatment Landscape of Biliary Tract Cancers
Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.
Other Clinical Trials With Chemoimmunotherapy in Biliary Tract Cancers
Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.
Chemoimmunotherapy in Biliary Tract Cancers: Data From TOPAZ-1
Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.
Biliary Tract Cancers: Standard of Care Treatment Strategies
Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.
What is the Role of Biomarker Testing in Biliary Tract Cancers?
Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.
Overview of Biliary Tract Cancers and Diagnosis
Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.
Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Novel Targeted Therapies Under Investigation in Biliary Tract Cancers
Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.
Biliary Tract Cancers: Combination Strategies With Immune Checkpoint Inhibitors
An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.
TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers
Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.
Standard of Care Systemic Therapies for Biliary Tract Cancers
Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.
Role for Liver Transplant in Biliary Tract Cancers
A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.
Liver-Directed Treatment Strategies in Biliary Tract Cancers
A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.
Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies
Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.
Advent of Molecular Testing in Biliary Tract Cancers
Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.
Optimizing the Staging of Biliary Tract Cancers
Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.
Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers
Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.
Overview on Biliary Tract Cancers and Their Rising Incidence
Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.
Advanced Biliary Tract Cancers: Novel Biomarker Strategies
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Novel Agents Being Explored in Advanced Biliary Tract Cancers
Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
Sequencing Therapy in Patients With Advanced Biliary Tract Cancers
In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy
Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
An Overview of Systemic Therapy for Advanced Biliary Tract Cancers
Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
What is the Role of Transplant in Early-Stage Biliary Tract Cancers?
Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
Treatment Options for Early-Stage Biliary Tract Cancers
Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Guidelines for Molecular Testing in Biliary Tract Cancers
Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma
Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512